| Bioactivity | RGH-5526 (GYKI-11679) is a new antihypertensive agent. |
| In Vivo | RGH-5526 (GYKI-11679) is a new antihypertensive agent. Results show a sharp (61%) reduction in the hypothalamic Noradrenaline (NA) level 2 h after the administration of 10 mg/kg of RGH-5526, and this effect lasts for 4 to 6 h. It is demonstrated that RGH-5526 exerts a greater NA lowering effect in the hypothalamus than in the periphery. RGH-5526 does not influence the hypothalamic monoamine oxidase (MAO)-activity following prolonged treatment[1]. |
| Name | RGH-5526 |
| CAS | 69579-13-1 |
| Formula | C16H25N5O3 |
| Molar Mass | 335.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Huszti Z, et al. Influence on turnover and level of hypothalamic noradrenaline by a new antihypertensive agent (GYKI 11679). J Neurochem. 1981 Nov;37(5):1272-81. |